BR0213953A - Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a factor v or factor v-related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce coagulation time, to enhance haemostasis, to prolong clot lysis time in a subject, and to increase clot resistance in a subject, kit containing a treatment for bleeding episodes - Google Patents

Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a factor v or factor v-related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce coagulation time, to enhance haemostasis, to prolong clot lysis time in a subject, and to increase clot resistance in a subject, kit containing a treatment for bleeding episodes

Info

Publication number
BR0213953A
BR0213953A BR0213953-7A BR0213953A BR0213953A BR 0213953 A BR0213953 A BR 0213953A BR 0213953 A BR0213953 A BR 0213953A BR 0213953 A BR0213953 A BR 0213953A
Authority
BR
Brazil
Prior art keywords
factor
subject
related polypeptide
bleeding episodes
factor vii
Prior art date
Application number
BR0213953-7A
Other languages
Portuguese (pt)
Inventor
Rasmus R Jkjaer
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BR0213953A publication Critical patent/BR0213953A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, KIT DE PARTES, USO DE FATOR VII OU UM POLIPEPTìDEO RELACIONADO COM FATOR VII EM COMBINAçãO COM UM FATOR V OU UM POLIPEPTìDEO RELACIONADO COM FATOR V, USO DE UMA COMPOSIçãO, MéTODOS PARA TRATAR EPISóDIOS DE SANGRAMENTO EM UM SUJEITO, PARA REDUZIR O TEMPO DE COAGULAçãO, PARA INTENSIFICAR HEMóSTASE, PARA PROLONGAR O TEMPO DE LISE DE COáGULOS EM UM SUJEITO, E PARA INCREMENTAR A RESISTêNCIA DO COáGULO EM UM SUJEITO, KIT CONTENDO UM TRATAMENTO PARA EPISóDIOS DE SANGRAMENTO". A presente invenção refere-se a uma composição compreendendo Fator VII ou um polipeptídeo relacionado com Fator VII, e Fator V ou um polipeptídeo relacionado com Fator V, e ao uso da mesma para tratar episódios de sangramento, como para reduzir tempo de coagulação, intensificar hemóstase ou incrementar a resistência do coágulo."PHARMACEUTICAL COMPOSITION, PARTS KIT, USE OF FACTOR VII OR A FACTOR-RELATED POLYPEPTIDE IN COMBINATION WITH A FACTOR V OR A FACTOR-RELATED POLYPEPTIDE, METHODS FOR TREATING A BLOOD EPISODE EPISODE COAGULATION TIME, TO INCREASE HEMOSASIS, TO EXTEND CLOCK LISING TIME IN A SUBJECT, AND TO INCREASE THE COGULES RESISTANCE IN A SUBJECT, KIT CONTAINING BLOOD EPISODE TREATMENT ". The present invention relates to a composition comprising Factor VII or a Factor VII-related polypeptide, and Factor V or a Factor V-related polypeptide, and its use to treat bleeding episodes, such as to reduce clotting time, to enhance haemostasis or increase clot resistance.

BR0213953-7A 2001-11-09 2002-11-05 Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a factor v or factor v-related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce coagulation time, to enhance haemostasis, to prolong clot lysis time in a subject, and to increase clot resistance in a subject, kit containing a treatment for bleeding episodes BR0213953A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101660 2001-11-09
PCT/DK2002/000736 WO2003039584A1 (en) 2001-11-09 2002-11-05 Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides

Publications (1)

Publication Number Publication Date
BR0213953A true BR0213953A (en) 2004-08-31

Family

ID=8160820

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213953-7A BR0213953A (en) 2001-11-09 2002-11-05 Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a factor v or factor v-related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce coagulation time, to enhance haemostasis, to prolong clot lysis time in a subject, and to increase clot resistance in a subject, kit containing a treatment for bleeding episodes

Country Status (16)

Country Link
EP (1) EP1446149A1 (en)
JP (1) JP2005511599A (en)
KR (1) KR20050043734A (en)
CN (1) CN1596125A (en)
AU (1) AU2002340779B2 (en)
BR (1) BR0213953A (en)
CA (1) CA2464615A1 (en)
CZ (1) CZ2004543A3 (en)
HU (1) HUP0401985A3 (en)
IL (1) IL161544A0 (en)
MX (1) MXPA04004304A (en)
NO (1) NO20042380L (en)
PL (1) PL370634A1 (en)
RU (1) RU2004117534A (en)
WO (1) WO2003039584A1 (en)
ZA (1) ZA200403271B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200116B1 (en) 1999-07-14 2008-10-15 Novo Nordisk Health Care AG USE OF FVIIa OR A TISSUE FACTOR AGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
CN101870729A (en) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
EP1713497B1 (en) * 2004-02-05 2016-04-13 Novo Nordisk Health Care AG Use of factor viia for treating late complications of trauma
FR2894831B1 (en) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement THROMBIN FREE BIOLOGICAL GLUE AND USE THEREOF AS MEDICAMENT.
ES2399138T3 (en) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Local treatment with factor VII
BR112016009954A2 (en) * 2013-11-04 2017-12-05 Univ California therapy for the treatment or prevention of conditions associated with hypocoagulation bleeding

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0756638T3 (en) * 1994-04-22 2001-07-23 Sanquin Bloedvoorziening Means for the treatment of disorders of the blood coagulation cascade
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
WO1999058699A2 (en) * 1998-05-14 1999-11-18 Battelle Memorial Institute Transgenic plant-derived human blood coagulation factors

Also Published As

Publication number Publication date
NO20042380L (en) 2004-06-08
WO2003039584A1 (en) 2003-05-15
PL370634A1 (en) 2005-05-30
IL161544A0 (en) 2004-09-27
KR20050043734A (en) 2005-05-11
CA2464615A1 (en) 2003-05-15
AU2002340779B2 (en) 2007-08-02
HUP0401985A2 (en) 2004-12-28
HUP0401985A3 (en) 2009-03-30
ZA200403271B (en) 2004-11-08
CN1596125A (en) 2005-03-16
EP1446149A1 (en) 2004-08-18
CZ2004543A3 (en) 2004-08-18
RU2004117534A (en) 2005-05-10
JP2005511599A (en) 2005-04-28
MXPA04004304A (en) 2004-08-11

Similar Documents

Publication Publication Date Title
BR0110659A (en) Pharmaceutical composition, kit, use of a factor viia in combination with a factor, xiii, and methods for enhancing fibrin clot formation in an individual and for treating bleeding episodes in an individual
BR0207006A (en) Pharmaceutical composition, kit, use of a factor vii preparation or factor vii-related polypeptide in combination with a preparation of a factor ix or factor ix-related polypeptide, use of a composition, method for treating bleeding episodes in a patient , to reduce clotting time in a patient, to intensify hemostasis in a patient, to reduce the number of coagulation factor protein administrations needed to stop bleeding and maintain hemostasis in a patient, to reduce the amount of protein of the administered clotting factor needed to halt bleeding and maintain a patient's hemostasis, to prolong clot lysis time in a patient, to increase clot resistance in a patient, and to intensify fibrin clot formation in a patient. a patient
ATE467425T1 (en) TARGETED DELIVERY OF PHARMACEUTICAL AGENTS TO INJURED TISSUES
ATE485371T1 (en) VARIANTS OF THE HUMAN COAGULATION FACTOR VII
BR9812965A (en) Methods for treating hypercoagulable states or acquired protein deficiency
BR9812228A (en) Fibrin sponge, process for preparing it, use of a fibrin sponge, and, kit.
EA200400849A1 (en) MIXTURE COMPOSITIONS FOR BABIES, CONTAINING THE INCREASED QUANTITIES OF ALPHA-LACTALBUMIN
ATE454403T1 (en) HUMAN COAGULATION FACTOR VII POLYPEPTIDES
BR0210282A (en) Calcium phosphate delivery vehicles for osteoinductive proteins
FR2767833B1 (en) ISOLATED SKIN POLYPEPTIDE AND ITS USE
AR035786A2 (en) VARIANTS OF COAGULATION FACTORS DEPENDENT ON VITAMIN K AND COMPOSITIONS CONTAINING THEM
ATE285219T1 (en) RECOMBINANT HAIR TREATMENTS
MXPA03006771A (en) Modified antibodies and methods of use.
MX9606386A (en) Agents affecting thrombosis hemostasis.
TW200407425A (en) Human coagulation factor VII polypeptides
ES2063365T3 (en) ANTICOAGULANT COMPOSITIONS BASED ON THE XA FACTOR.
BR0211256A (en) Pharmaceutical composition, kit, uses of a factor vii or factor vii-related polypeptide in combination with a factor xi or factor xi-related polypeptide and a composition, and methods for treating bleeding episodes in a patient to reduce time of coagulation in one patient, to intensify hemostasis in one patient, to prolong clot lysis time and to increase clot resistance in one patient
Nandish et al. Anticoagulant, antiplatelet and fibrin clot hydrolyzing activities of flax seed buffer extract
TR199802394A2 (en) Developed process to stabilize proteins.
BR0213953A (en) Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a factor v or factor v-related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce coagulation time, to enhance haemostasis, to prolong clot lysis time in a subject, and to increase clot resistance in a subject, kit containing a treatment for bleeding episodes
BR9911917A (en) Compositions comprising gaba and caffeine analogs
EA199700241A1 (en) NEW, DETERMINED BY COMPOSITION OF A MIXTURE OF ENZYMES FOR ISOLATION OF CELLS AND TREATMENT OF THE RAS
ATE395602T1 (en) USE OF HMGB PROTEINS AND NUCLEIC ACIDS CODING THEREOF
BRPI0416461A (en) method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide
BR0213952A (en) Pharmaceutical composition, kit of parts, use of factor vii or a factor vii-related polypeptide in combination with a parent-1 or parent-1 related polypeptide, use of a composition, methods for treating bleeding episodes in a subject, to reduce clotting time in one subject, to intensify hemostasis in one subject, to prolong clot lysis time in one subject, and to increase clot resistance in one subject, and kit containing a treatment for bleeding episodes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.